Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Current Deferred Revenue (2016 - 2026)

Oramed Pharmaceuticals filings provide 10 years of Current Deferred Revenue readings, the most recent being $1.4 million for Q4 2025.

  • Quarterly Current Deferred Revenue changed N/A to $1.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Dec 2025, changed N/A year-over-year, with the annual reading at $1.4 million for FY2025, N/A changed from the prior year.
  • Current Deferred Revenue hit $1.4 million in Q4 2025 for Oramed Pharmaceuticals, up from $986000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $2.7 million in Q1 2021 and bottomed at $674000.0 in Q1 2023.
  • Average Current Deferred Revenue over 4 years is $1.9 million, with a median of $2.0 million recorded in 2022.
  • The largest annual shift saw Current Deferred Revenue changed 0.0% in 2021 before it plummeted 66.3% in 2023.
  • Oramed Pharmaceuticals' Current Deferred Revenue stood at $2.7 million in 2021, then plummeted by 50.43% to $1.3 million in 2022, then crashed by 49.7% to $674000.0 in 2023, then skyrocketed by 100.74% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Current Deferred Revenue are $1.4 million (Q4 2025), $986000.0 (Q3 2025), and $1.2 million (Q2 2025).